Phaseline

Companies › GigaGen

GigaGen: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Infectious disease, Oncology; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GIGA-564–Phase 1Advanced or Metastatic Solid Tumor MalignanciesNov 2027
GIGA-2339–Phase 1Hepatitis B Virus InfectionNov 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06258304GIGA-564Phase 1Advanced or Metastatic Solid Tumor MalignanciesOncologyNov 2027
NCT07024641GIGA-2339Phase 1Hepatitis B Virus InfectionInfectious diseaseNov 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.